Healthy adults
Conditions
Interventions
Ingestion of test supplement for 24 consecutive weeks
Sponsors
TTC Co.,Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Subjects aged from 45 to 65 years old (2) Subjects with low contrast sensitivity
Exclusion criteria
Exclusion criteria: (1) Subjects who have eye disease except refractive errors (e.g., Macular disease, optic media with advanced abnormalities) (2) Subject who are myopia over -6D (3) Subject who are daily corrected visual acuity less than 0.7 in both eyes (4) Subjects who are best corrected visual acuity of less than 1.0 (5)Subjects who have under treatment or a history of serious disease (e.g., diabetes, liver disease, kidney disease, or heart disease) (6)Subjects who have history of surgical resection of the gastrointestinal tract (except for appendectomy) (7) Subjects who routinely take lutein or zeaxanthin containing supplement within the past year (8) Subjects who have history of smoking within the past year (9) Subjects who routinely take medicine (including eye drops) or health foods that may affect the results of this study (10) Subjects who may have symptoms of hay fever during study period (11) Subjects having possibilities for emerging allergy related to the study (12) Subjects who are in long-term treatment (including medication, hospitalization, diet and exercise therapy )or are planning to take treatment during study period (13) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire (14) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination on baseline examination (15) Subjects who intend to become pregnant or lactating (16) Subjects who have participated in other clinical study (17) Subjects who are judged as unsuitable by doctor for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Contrast sensitivity | — |
Secondary
| Measure | Time frame |
|---|---|
| Macular pigment optical density, Subjective symptom questionnaire, Visual acuity, Best corrected visual acuity, Serum lutein and zeaxanthin concentration | — |
Countries
Japan
Contacts
Public ContactHiroyasu Shimada
TTC Co.,Ltd. Clinical Research Planning Department
Outcome results
None listed